Copy of Biomedical Sciences Mockup
Professor Rob Cross, Warwick Medical School has been awarded the Biochemical Society Award for Sustained Excellence 2025
Microbiology and Infection
With a unique combination of experimental and bioinformatics researchers we tackle fundamental challenges including the evolution of pathogenic bacteria, host-pathogen interactions and development of new antimicrobials.
Cell & Developmental Biology
Exploring the cellular basis of disease, the mechanisms that enable cell duplication, movement and repair and the self-organisational events that produce multi-cellular organisms
Translational & Experimental Medicine
From biological clocks to metabolism, reproductive health, new biomaterials and devices - our vision is to drive improvements in human health and disease.
Welcome to Biomedical Sciences
The Biomedical Sciences Directorate (BMS) has a vision to build world-class Discovery Science and Translational Medicine programmes in partnership with the University Hospital Coventry & Warwickshire (UHCW); deliver interdisciplinary educational programmes; and transmit new knowledge to the wider world through an exciting public engagement interface.
Hear from our Director of Biomedical Sciences
***Awaiting content
Professor Anne Straube - Director of Biomedical Sciences
Our Impact
Our mission is to advance world-class discovery science with an interdisciplinary approach to unravel the fundamental mechanisms of physiological and pathological processes; develop pioneering diagnostic and preventive technologies; and deliver ground-breaking treatments for a healthier future for all. In particular, we are interested in the cross-cutting themes of technology and methodology; translational and clinical research and Women's Health.
Our research is grouped into Cell & Mechano-Biology, Host-Pathogen Interactions and Reproductive Biomedicine.
Facilities
Our laboratory facilities include state of the art buildings. These facilities include open-plan layouts; shared equipment and co-located offices and write-up spaces.
Potentially use slider block below for building images and content which links through to modals for equipment??
Computing and Advanced Microscopy Development Unit (CAMDU)
CAMDU is home to multiple commercial light microscopes and custom-built systems alongside Wellcome-funded lattice light sheet microscopy and visitor programme (coming soon); computational workstations, software development and petabyte data storage array are also in place.
Bioinformatics Support
The Division provides support for bioinformatics activities by means of two dedicated Research Fellows with expertise in Genomics, Proteomics, Metabolomics, Data Storage and Analysis. PIs should submit an Expression of Interest Form for projects involving substantial support.
Cyber-Infrastructure for Microbial Bioinformatics
Entrobase provides resources for analyzing and visualizing genomic variation within 1000s of Escherichia coli and Salmonella genomes. The MRC Cloud Infrastructure for microbial bioinformatics provides access to computing power, storage and bioinformatics tools.
Electron Microscopy
The University's Research Technology Platform houses a transmission cryo-electron microscope with in-column energy filter and a top of the line director electron detector and is a partner in the MRC-funded midlands Cryo-EM facility which will deliver access to 300Kv instrumentation.
Proteomics
The Proteomics Research Technology Platform undertakes collaborative projects with both UK and international academic or commercial institutions using protein profiling, quantitative proteomic studies, phosphorylation and post-translational modification mapping.
Zebrafish
Our 1200-tank aquatics system is built with support from the Warwick Medical School and the Wellcome Trust. The facility supports zebrafish research by groups accross the University, to address questions of fundamental and biomedical relevance.
Computing and Advanced Microscopy Development Unit (CAMDU)
CAMDU is home to multiple commercial light microscopes and custom-built systems alongside Wellcome-funded lattice light sheet microscopy and visitor programme (coming soon); computational workstations, software development and petabyte data storage array are also in place.
Learn moreBioinformatics Support
The Division provides support for bioinformatics activities by means of two dedicated Research Fellows with expertise in Genomics, Proteomics, Metabolomics, Data Storage and Analysis. PIs should submit an Expression of Interest Form for projects involving substantial support.
Learn moreCyber-Infrastructure for Microbial Bioinformatics
Entrobase provides resources for analyzing and visualizing genomic variation within 1000s of Escherichia coli and Salmonella genomes. The MRC Cloud Infrastructure for microbial bioinformatics provides access to computing power, storage and bioinformatics tools.
Learn moreElectron Microscopy
The University's Research Technology Platform houses a transmission cryo-electron microscope with in-column energy filter and a top of the line director electron detector and is a partner in the MRC-funded midlands Cryo-EM facility which will deliver access to 300Kv instrumentation.
Learn moreProteomics
The Proteomics Research Technology Platform undertakes collaborative projects with both UK and international academic or commercial institutions using protein profiling, quantitative proteomic studies, phosphorylation and post-translational modification mapping.
Learn moreZebrafish
Our 1200-tank aquatics system is built with support from the Warwick Medical School and the Wellcome Trust. The facility supports zebrafish research by groups accross the University, to address questions of fundamental and biomedical relevance.
Learn moreKey People **link to people page for info below - condense block copy
The Biomedical Sciences directorate at Warwick is home to over 40 Principal Investigators, including clinical and non-clinical academics. The directorate also has several joint appointments with other departments to develop interdisciplinary research.
Our achievements in recent years include:
- 7 Wellcome Investigator/Discovery Award holders; 2 Wellcome/Royal Society Fellowships; 1 CRUK Programme Grant holder; and 1 Leverhulme International Professor
- Being home to the MRC Doctoral Training Partnership in Interdisciplinary Biomedical Research; Wellcome-Warwick Translational Partnership; MRC Innovation Accelerator Account and the Tommy’s National Centre for Miscarriage Research
- Achieving 2 x Hooke Medals from the British Society for Cell Biology and 1 x Lister Research Prize- Having 3 members of the Wellcome expert advisory groups (including one chair) and 5 members of UKRI (MRC and BBSRC) grant panels or pool of experts
- Having 1 member of the HFSP grant panel and 1 member of the CRUK grant panel- Having a Director of the Company of Biologists- Having 1 EMBO member in our team and 1 EMBO Global Investigator
Actin arginylation alters myosin engagement and F-actin patterning despite structural conservation
StayRose: a photostable StayGold derivative red-shifted by genetic code expansion
Cyclic Peptide–Polymer Conjugate Nanotubes for Delivery of SN-38 in Treatment of Colorectal Cancer Model
New Dual-Action Antimicrobial Polymers with Anti-Inflammatory Properties
Challenges
Eliminate Pain from Endometriosis
Endometriosis is the growth of tissue like the uterine lining (endometrium) outside the uterus, usually within the pelvic cavity as ‘endometriosis lesions’. The result is chronic pain, infertility and diminished quality of life - 190 million women world wide are affected.
Endometriosis is currently diagnosed by invasive surgery and is treated by surgical removal of lesions or with drugs that suppress sex hormones. Sadly, in many women symptoms recur after surgery and available medical treatments have undesirable side-effects and are contraceptive. New non-invasive diagnostic approaches and treatments for endometriosis are desperately needed.
Breakthroughs:
Our research has focussed on preclinical disease model development and optimisation in the field of endometriosis. We have used these disease models to provide vital insight into the pathophysiology of the disorder, with a specific focus on role of the immune system. We now know enough about particular immune cells to begin to target them therapeutically, with our first phase 1 clinical trial funded and poised to begin recruiting patients. We are also performing research into how peripheral blood immune cells can be exploited for diagnostic purposes. Our vision is to provide new, non-hormonal medical therapies for endometriosis and revolutionise non-invasive diagnosis of the disorder, collectively enhancing the lives of millions of women worldwide. Alongside, we are developing behaviour change interventions in the management of long-term pain including those with endometriosis. Together these breakthroughs will improve the quality of life of women with endometriosis.
Challenge Lead
Dr. Erin Greaves
Challenges
Eliminate Pain from Endometriosis
Endometriosis is the growth of tissue like the uterine lining (endometrium) outside the uterus, usually within the pelvic cavity as ‘endometriosis lesions’. The result is chronic pain, infertility and diminished quality of life - 190 million women world wide are affected.
Endometriosis is currently diagnosed by invasive surgery and is treated by surgical removal of lesions or with drugs that suppress sex hormones. Sadly, in many women symptoms recur after surgery and available medical treatments have undesirable side-effects and are contraceptive. New non-invasive diagnostic approaches and treatments for endometriosis are desperately needed.
Breakthroughs:
Our research has focussed on preclinical disease model development and optimisation in the field of endometriosis. We have used these disease models to provide vital insight into the pathophysiology of the disorder, with a specific focus on role of the immune system. We now know enough about particular immune cells to begin to target them therapeutically, with our first phase 1 clinical trial funded and poised to begin recruiting patients. We are also performing research into how peripheral blood immune cells can be exploited for diagnostic purposes. Our vision is to provide new, non-hormonal medical therapies for endometriosis and revolutionise non-invasive diagnosis of the disorder, collectively enhancing the lives of millions of women worldwide. Alongside, we are developing behaviour change interventions in the management of long-term pain including those with endometriosis. Together these breakthroughs will improve the quality of life of women with endometriosis.
Challenge Lead
Dr. Erin Greaves
Challenges
Eliminate Pain from Endometriosis
Endometriosis is the growth of tissue like the uterine lining (endometrium) outside the uterus, usually within the pelvic cavity as ‘endometriosis lesions’. The result is chronic pain, infertility and diminished quality of life - 190 million women world wide are affected.
Endometriosis is currently diagnosed by invasive surgery and is treated by surgical removal of lesions or with drugs that suppress sex hormones. Sadly, in many women symptoms recur after surgery and available medical treatments have undesirable side-effects and are contraceptive. New non-invasive diagnostic approaches and treatments for endometriosis are desperately needed.
Breakthroughs:
Our research has focussed on preclinical disease model development and optimisation in the field of endometriosis. We have used these disease models to provide vital insight into the pathophysiology of the disorder, with a specific focus on role of the immune system. We now know enough about particular immune cells to begin to target them therapeutically, with our first phase 1 clinical trial funded and poised to begin recruiting patients. We are also performing research into how peripheral blood immune cells can be exploited for diagnostic purposes. Our vision is to provide new, non-hormonal medical therapies for endometriosis and revolutionise non-invasive diagnosis of the disorder, collectively enhancing the lives of millions of women worldwide. Alongside, we are developing behaviour change interventions in the management of long-term pain including those with endometriosis. Together these breakthroughs will improve the quality of life of women with endometriosis.
Challenge Lead
Dr. Erin Greaves
Challenges
Eliminate Pain from Endometriosis
Endometriosis is the growth of tissue like the uterine lining (endometrium) outside the uterus, usually within the pelvic cavity as ‘endometriosis lesions’. The result is chronic pain, infertility and diminished quality of life - 190 million women world wide are affected.
Endometriosis is currently diagnosed by invasive surgery and is treated by surgical removal of lesions or with drugs that suppress sex hormones. Sadly, in many women symptoms recur after surgery and available medical treatments have undesirable side-effects and are contraceptive. New non-invasive diagnostic approaches and treatments for endometriosis are desperately needed.
Breakthroughs:
Our research has focussed on preclinical disease model development and optimisation in the field of endometriosis. We have used these disease models to provide vital insight into the pathophysiology of the disorder, with a specific focus on role of the immune system. We now know enough about particular immune cells to begin to target them therapeutically, with our first phase 1 clinical trial funded and poised to begin recruiting patients. We are also performing research into how peripheral blood immune cells can be exploited for diagnostic purposes. Our vision is to provide new, non-hormonal medical therapies for endometriosis and revolutionise non-invasive diagnosis of the disorder, collectively enhancing the lives of millions of women worldwide. Alongside, we are developing behaviour change interventions in the management of long-term pain including those with endometriosis. Together these breakthroughs will improve the quality of life of women with endometriosis.
Challenge Lead
Dr. Erin Greaves